Biofeedback for treatment of irritable bowel syndrome

Cochrane Database of Systematic Reviews

Volumn 2017, Issue 1, 2017, Pages

  Goldenberg, Joshua Z ^a   Brignall, Matthew ^a   Hamilton, Michelle ^a   Beardsley, Jennifer ^a   Lichtenstein, Brad ^a  

^a BASTYR UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; FEEDBACK SYSTEM; HUMAN; IRRITABLE COLON; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SAFETY; SYSTEMATIC REVIEW; THERAPY EFFECT;

EID: 85011026231     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD012530     Document Type: Article

References (26)

1. Association for Applied Psychophysiology and Biofeedback. About Biofeedback. www.aapb.org/i4a/pages/index.cfm?pageid=3463 Accessed 23 January 2016.
2. Akl EA, Kahale LA, Agoritsas T, Bringnardello-Petersen R, Busse JW, Carrasco-Labra A, et al. Handling trial participants with missing outcome data when conducting a meta-analysis: a systematic survey of proposed approaches. Systematic Reviews 2015;4:98.
3. Canavanm C, West J, Card T. The epidemiology of irritable bowel syndrome. Clinical Epidemiology 2014;6:71-80.
4. Deeks JJ, Higgins JPT, Altman DG (editors). Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S (editors) editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
5. Dobbin A, Dobbin J, Ross SC, Graham C, Ford MJ. Randomised controlled trial of brief intervention with biofeedback and hypnotherapy in patients with refractory irritable bowel syndrome. Journal of the Royal College of Physicians of Edinburgh 2014;43(1):15-23.
6. Doshi JA, Cai Q, Buono JL, Spalding WM, Sarocco P, Tan H, et al. Economic burden of irritable bowel syndrome with constipation: a retrospective analysis of health care costs in a commercially insured population. Journal of Managed Care and Specialty Pharmacy 2014;20(4):382-90.
7. Drossman DA, Hasler WL. Rome IV - Functional GI Disorders: Disorders of Gut-Brain Interaction. Gastroenterology 2016;150(6):1257-61.
8. Ebrahim S, Akl EA, Mustafa RA, Sun X, Walter SD, Heels-Ansdell D, et al. Addressing continuous data for participants excluded from trial analysis: a guide for systematic reviewers. Journal of Clinical Epidemiology 2013;66(9):1014-21.
9. FDA Guidance for Industry Irritable Bowel Syndrome - Clinical Evaluation of Drugs for Treatment. http://www.fda.gov/downloads/Drugs/.../Guidances/UCM205269.pdf Accessed 28 December 2016.
10. Gagnier JJ, Morgenstern H, Altman DG, Berlin J, Chang S, McCulloch P, et al. Consensus-based recommendations for investigating clinical heterogeneity in systematic reviews. BMC Medical Research Methodology 2013;13:106.
11. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter, Alonso-Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008;336:924-6.
12. Halland M, Saito Y. Irritable bowel syndrome: new and emerging treatments. BMJ 2015;350:h1622.
13. Harbord R, Egger M, Sterne J. A modified test for small-study effects in meta-analyses of controlled trials with binary endpoints. Statistics in Medicine 2006;25(20):3443-57.
14. Hartling L, Ospina M, Liang Y, Dryden D, Hooton N, Seida JK, et al. Risk of bias versus quality assessment of randomised controlled trials: cross sectional study. BMJ 2009;339:1017-23.
15. Higgins JPT, Altman DG, Sterne JAC (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
16. Kim J, Lin E, Pimentel M. Biomarkers of Irritable Bowel Syndrome. Journal of Neurogastroenterology and Motility 2017;23(1):20-6.
17. Lee YJ, Park KS. Irritable bowel syndrome: emerging paradigm in pathophysiology. World Journal of Gastroenterology 2014;20(10):2456-69.
18. MacDougall JE, Johnston JM, Lavins BJ, Nelson LM, Williams VS, Carson RT, et al. An evaluation of the FDA Responder Endpoint for IBS-C clinical trials: analysis of data from linaclotide Phase 3 clinical trials. Neurogastroenterology and Motility 2013;25(6):481-6.
19. Pellissier S, Dantzer C, Canini F, Mathieu N, Bonaz B. Psychological adjustment and autonomic disturbances in inflammatory bowel diseases and irritable bowel syndrome. Psychoneuroendocrinology 2010;35(5):653-62.
20. Peper E, Harvey R, Takabayashi N. Biofeedback an evidence based approach in clinical practice. Japanese Journal of Biofeedback Research 2009;36(1):3-10.
21. Popay J, Roberts H, Sowden A, Petticrew M, Britten N, Arai L, Roen K, Rodgers M. Developing methods for the narrative synthesis of quantitative and qualitative data in systematic reviews of effects. Centre for Reviews and Dissemination 2006.
22. Sowder E, Gevirtz R, Shapiro W, Ebert C. Restoration of vagal tone: a possible mechanism for functional abdominal pain. Applied Psychophysiology and Biofeedback 2010;35(3):199-206.
23. Sterne J, Sutton A, Ioannidis J, Terrin N, Jones D, Lau J, et al. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ 2011;343:d4002.
24. Sun X, Briel M, Busse JW, You JJ, Akl EA, Mejza F, et al. Credibility of claims of subgroup effects in randomized controlled trials: systematic review. BMJ 2012;344:e1553.
25. Wheat AL, Larkin KT. Biofeedback of heart rate variability and related physiology: a critical review. Applied Psychophysiology and Biofeedback 2010;35(3):229-42.
26. Zijdenbos IL, de Wit NJ, van der Heijden GJ, Rubin G, Quartero AO. Psychological treatments for the management of irritable bowel syndrome. Cochrane Database of Systematic Reviews 2009, Issue 1. [DOI: 10.1002/14651858.CD006442.pub2]